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Melioidosis, a disease caused by the bacterium Burkholderia pseudomallei, is endemic in southeast Asia and
northern Australia. We used suppression subtractive hybridization (SSH) to identify sequences that varied
between two B. pseudomallei isolates from Australia and determined the distribution of 45 SSH-derived
sequences among a panel of B. pseudomallei and B. thailandensis isolates. Sequences exhibiting variable
prevalence were included in a variable amplicon typing (VAT) scheme designed to score the presence or
absence of 14 PCR amplicons. VAT analysis was carried out with 48 isolates from Thailand, which were typed
by multilocus sequence typing (MLST), and 44 isolates from Australia of known MLST type. The VAT scheme
could be used to divide the 48 isolates from Thailand into 23 VAT types and the 44 isolates from Australia into
36 VAT types. Some of the sequences included in the VAT scheme were more commonly PCR positive among
isolates from Australia than among isolates from Thailand, and vice versa. No isolate from Australia was PCR
positive for genomic island 11 or a putative transposase sequence, whereas four SSH-derived sequences were
far more prevalent among the Australian isolates. Analysis based on the VAT scheme indicated that the isolates
clustered into groups, some of which were mainly or exclusively from one geographical origin. One cluster
included Australian isolates that were mostly associated with severe disease, including rare neurological
melioidosis, suggesting that the content of the accessory genome may play an important role in determining the
clinical manifestation of the disease.
The disease melioidosis, caused by the gram-negative bac-
terium Burkholderia pseudomallei, is endemic in southeast Asia
and northern Australia (4). B. pseudomallei, a normal inhabit-
ant of soil and surface water in regions of endemicity, infects
via direct inoculation or inhalation and can cause severe sepsis
or pneumonia. Not only can melioidosis affect many different
sites in the body, but it also has a wide spectrum of severity,
ranging from acute and often fatal sepsis to more chronic
disease (8, 16, 28). Several years ago, B. pseudomallei was
separated from an avirulent biotype lacking the ability to as-
similate arabinose, now known as B. thailandensis (24). How-
ever, it is clear that the levels of virulence exhibited by different
B. pseudomallei isolates can vary considerably in animal models
(26). Such variations can occur between related strains and do
not necessarily correlate with clinical outcome or the source of
the isolate (26).
Various typing methods have been applied to the study of
genetic variation among B. pseudomallei populations (14, 18),
including molecular fingerprinting approaches such as ribotyp-
ing (13), random amplified polymorphic DNAs (RAPDs) (17,
26), and macrorestriction analysis coupled with pulsed-field gel
electrophoresis (PFGE) (5, 15, 26). More recently, a multilo-
cus sequence typing (MLST) scheme has been developed (11).
Extensive typing of isolates by MLST has demonstrated that
isolates from Australia differ from those isolated elsewhere (6),
but there was no correlation between strain type and clinical
presentation, a finding supported by analysis by PFGE (4).
Molecular typing methods often suffer from the lack of port-
ability (RAPDs), the requirement for specialized equipment
(PFGE), the length of the procedures (PFGE and MLST), or
the cost (MLST). MLST has emerged as a preferred typing
method for phylogenetic studies because of its portability and
unequivocal output data. However, MLST typing specifically
targets the conserved regions of bacterial genomes rather than
the accessory genome, which may have an important role to
play in virulence. The genome sequence of B. pseudomallei
K96243 revealed the presence of 16 genomic islands (GIs) with
variable distributions among B. pseudomallei isolates, suggest-
ing that horizontal gene transfer has played an important role
in the evolution of this pathogen (12). More recently, 16 re-
gions of difference (RDs) in the genome of strain K96243, 13
of which corresponded to the GIs, were reported following a
comparison with strain Bp15682 by the use of microarrays (22).
Other studies have provided further evidence of considerable
variations in the accessory genome of B. pseudomallei (9, 21).
Subtractive hybridization is a powerful technique for the
identification of DNA sequences present in one strain (the
tester) but absent from another (the driver or reference), and
it has widely been applied to the study of bacterial pathogens
(29), including B. pseudomallei and its close relative, B. mallei
(9, 10, 20). In this study we describe the use of suppression
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TABLE 1. Strains used in this studya
Isolate(s) Country Source; notesb MLSTgroupc
Allele no.
ace gltB gmhD lepA lipA narK ndh
B. pseudomallei isolates for
subtraction and
distribution analysis
338d Australia Melioidosis (chronic) 243 1 2 13 4 15 12 1
520d Australia Melioidosis (fulminant) ND ND ND ND ND ND ND ND
146 (VE05) Australia Goat isolate; same ribotype as 511 (B);
LD50 of 9.01  102
ND ND ND ND ND ND ND ND
511 (VE02) Australia Goat isolate, same ribotype as 146 (B);
LD50 of 6.32  104
ND ND ND ND ND ND ND ND
157 (CL26) Australia Melioidosis (A); LD50 of 3.00  100 ND ND ND ND ND ND ND ND
161 (VE06) Australia Sheep isolate (A); LD50 of 8.00  100 ND ND ND ND ND ND ND ND
169 (EN11) Australia Soil isolate (A); LD50 of 5.00  100 ND ND ND ND ND ND ND ND
244 (EN10) Australia Soil isolate (B); LD50 of 8.43  102 ND ND ND ND ND ND ND ND
186 (VE03) Australia Soil isolate (B); LD50 of 7.82  103 ND ND ND ND ND ND ND ND
265 (EN07) Australia Soil isolate (B); LD50 of 4.25  103 ND ND ND ND ND ND ND ND
295 (EN08) Australia Soil isolate (B); LD50 of 3.13  103 ND ND ND ND ND ND ND ND
1655 Australia From patient with long-term carriage ND ND ND ND ND ND ND ND
E503 Malaysia Melioidosis ND ND ND ND ND ND ND ND
E505 UK/Goa Clinical isolate ND ND ND ND ND ND ND ND
E506 Malaysia Melioidosis ND ND ND ND ND ND ND ND
E955 (204), E957 (576) Thailand Clinical isolates ND ND ND ND ND ND ND ND
E958, E8 (E960) Thailand Environmental isolates ND ND ND ND ND ND ND ND
G185 (K96243) Thailand Clinical isolate; genome sequence strain ND ND ND ND ND ND ND ND
B. thailandensis isolates for
subtraction and
distribution analysis
E82 (E959), E32, E111,
E125, E132, E135,
E216, E251, E253,
E254, E255, E260
Thailand T. Pitt ND ND ND ND ND ND ND ND
B. pseudomallei isolates
used for VAT analysis
(excluding 338)
303 Australia Tracheotomy isolate 36 1 7 14 7 1 12 11
332 Australia Human isolate 106 1 2 3 2 16 21 1
973 Australia Human isolate 107 1 2 3 4 1 8 1
1152 Australia Rectal swab isolate 108 1 2 3 2 6 22 1
64 Australia Blood isolate 109 1 2 13 4 1 19 1
1080 Australia Wound swab isolate 111 1 2 13 2 1 9 1
911 Australia Sputum isolate 112 1 2 13 16 1 22 1
502 Australia Soil isolate 114 1 3 3 4 1 24 1
875 Australia Urine isolate 115 1 4 3 2 4 26 1
1164 Australia Blood isolate 116 1 4 3 4 1 12 1
1153 Australia CSF isolate 117 1 4 13 14 8 22 11
978 Australia Blood isolate 118 1 4 14 2 1 8 1
789 Australia Human isolate 120 1 4 22 2 5 23 1
114 Australia Lesion nodule isolate 121 1 4 23 2 1 8 1
1357 Australia Human isolate 122 1 6 13 2 1 8 11
449 Australia Blood isolate 126 1 14 20 1 15 9 15
944 Australia Blood isolate 127 1 15 3 2 6 27 1
634 Australia Human isolate 128 1 15 13 2 8 12 1
668 Australia Blood isolate 129 1 15 13 2 1 22 1
614 Australia Prostate isolate 132 1 16 13 4 6 21 1
1128 Australia Skin lesion isolate 133 1 16 13 4 15 21 1
130 Australia Blood isolate 134 1 16 14 4 1 19 1
99 Australia Human isolate 135 1 17 13 4 15 22 1
129 Australia Right-foot wound isolate 138 4 2 14 4 1 6 1
239 Australia Blood isolate 140 4 7 3 4 1 19 1
362 Australia Urine isolate 141 4 16 3 4 1 9 6
983 Australia Throat isolate 142 8 2 3 4 1 19 1
1123 Australia Blood isolate 143 8 2 13 4 1 6 1
1168 Australia Blood isolate 144 8 2 13 15 1 27 1
1161 Australia Sputum isolate 146 10 2 3 4 3 2 1
1174 Australia Blood isolate 147 10 2 3 4 15 2 1
62 Australia Human isolate 148 10 15 3 4 3 22 1
356 Australia Blood isolate 149 11 2 14 2 1 6 1
272 Australia Sputum isolate 236 1 1 13 1 18 23 11
210 Australia Blood isolate 238 1 2 3 21 15 9 1
112C Australia Human isolate 241 1 2 13 2 8 6 1
253 Australia Right-foot ulcer 242 1 2 13 4 1 22 1
271 Australia Blood isolate 247 1 2 23 2 1 31 1
222 Australia Knee swab isolate 259 1 6 13 2 15 8 11
Continued on facing page
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subtractive hybridization (SSH) to identify sequences that vary
between two B. pseudomallei isolates from Australia. We fur-
ther study the distribution of such sequences among a panel of
B. pseudomallei isolates. Using this information and data from
previous studies, we describe the development of a portable
multiplex PCR (M-PCR)-based method to screen for the pres-
ence or absence of 14 PCR amplicons. Finally, we describe the
use of this variable amplicon typing (VAT) scheme for its
ability to discriminate between isolates from Australia and
Thailand.
MATERIALS AND METHODS
Bacterial strains. The isolates used in this study are listed in Table 1. The
Australian isolates chosen for SSH were isolate 338 and isolate 520. Isolate 338
was isolated from the sputum of a 50-year-old man with chronic lung disease who
had a mild clinical infection and intermittently positive sputum cultures over
several years, despite specific therapy for melioidosis. Isolate 520 was isolated
from a 62-year-old woman on corticosteroids for chronic lung disease who died
of progressive septicemic melioidosis pneumonia. Uniquely among 49 isolates
tested, strain 338 has been found in a mouse model to induce a strong immu-
noprotective capacity against subsequent infection with another strain (27).
The strain panel used to analyze the distribution of subtracted sequences
TABLE 1—Continued
Isolate(s) Country Source; notesb MLSTgroupc
Allele no.
ace gltB gmhD lepA lipA narK ndh
504 Australia Soil isolate 268 1 15 31 4 6 19 1
527 Australia Blood isolate 269 1 21 3 2 5 22 11
506 Australia Soil isolate 281 12 4 6 2 3 33 1
157 Australia Human isolate 284 13 15 13 4 6 6 11
139 PNG Abscess isolate 246 1 2 22 18 1 22 11
141 PNG Blood isolate 274 4 20 13 2 3 6 11
140 Fiji Abscess isolate 280 12 1 3 1 1 22 1
314 Malaysia Blood isolate 58 3 1 5 1 1 4 1
P1 Thailand Blood isolate; northeastern Thailand u 1 1 12 2 6 4 1
P2 Thailand Pus isolate; northeastern Thailand 16 1 2 2 1 1 10 1
P3 Thailand Pus isolate; south Thailand u 1 1 11 1 6 22 1
P4 Thailand Blood isolate; eastern Thailand 211 3 1 3 1 1 4 1
P5 Thailand Pus isolate; northeastern Thailand u 3 1 2 1 8 4 3
P6 Thailand Blood isolate; south Thailand 93 1 1 2 1 1 4 1
P7 Thailand Blood isolate; Bangkok, Thailand 307 1 2 3 1 1 3 1
P8 Thailand Sinus isolate; Bangkok, Thailand 51 3 1 2 3 1 4 3
P9 Thailand Pus isolate; south Thailand u 3 1 2 3 5 2 1
P11 Thailand Blood isolate; south Thailand u 3 2 3 1 1 4 1
P12 Thailand Urine isolate; Bangkok, Thailand 46 3 1 2 1 1 3 3
P14 Thailand Pleural fluid; Chiang Mai, Thailand u 1 4 3 4 n n 3
P15 Thailand Pleural fluid; Chiang Mai 56 3 1 4 1 1 4 1
P16, P22 Thailand Blood isolate; Chiang Mai 290 3 4 11 3 5 4 1
P17, P21 Thailand Blood isolate; Chiang Mai u 1 1 4 17 1 4 1
P18, P19 Thailand Blood isolate; Chiang Mai 167 1 1 4 1 1 3 1
P20 Thailand Blood isolate; Chiang Mai 70 3 4 11 3 5 4 6
P23 Thailand Blood isolate; Chiang Mai u 1 4 3 3 5 3 3
P24 Thailand Blood isolate; Chiang Mai u 1 1 4 17 1 3 1
P25 Thailand Pus isolate; Chiang Mai 17 1 2 3 1 1 1 1
P26 Thailand Pus isolate; Chiang Mai 10 1 1 13 1 1 1 1
P27 Thailand Pus isolate; Chiang Mai u 1 2 4 1 1 22 1
P28, P31 Thailand Pus isolate; Chiang Mai u 1 1 4 17 1 4 1
P29 Thailand Pus isolate; Chiang Mai u 4 12 13 2 1 2 1
P30, P45 Thailand Pus isolate; Chiang Mai u 3 2 3 1 1 4 1
P32 Thailand Pus isolate; Chiang Mai u 1 2 4 3 6 3 1
P33, P35 Thailand Pus isolate; Chiang Mai u 1 4 6 1 6 3 1
P34, P44 Thailand Pus isolate; Chiang Mai 70 3 4 11 3 5 4 6
P36 Thailand Pus isolate; Chiang Mai u 3 2 4 1 1 4 1
P37 Thailand Pus isolate; Chiang Mai u 4 1 2 2 6 4 1
P38 Thailand Sputum isolate; Chiang Mai 56 3 1 4 1 1 4 1
P39 Thailand Urine isolate; Chiang Mai 10 1 1 13 1 1 1 1
P40 Thailand Urine isolate; Chiang Mai u 4 1 2 2 6 4 1
P41 Thailand Urine isolate; Chiang Mai u 1 1 4 17 1 4 1
P42 Thailand Pleural fluid; Chiang Mai 70 3 4 11 3 5 4 6
P43 Thailand Blood isolate; Chiang Mai 10 1 1 13 1 1 1 1
P46 Thailand Sputum isolate; Chiang Mai 10 1 1 13 1 1 1 1
P47 Thailand Sputum isolate; Chiang Mai u 3 1 2 3 5 2 1
P48 Thailand Sputum isolate; Chiang Mai 46 3 1 2 1 1 3 3
P49 Thailand Sputum isolate; Chiang Mai 70 3 4 11 3 5 4 6
P50 Thailand Urine isolate; Chiang Mai 23 1 2 13 1 1 1 1
B. thailandensis isolate
used in VAT
analysis
E52 Thailand Water isolate; Chiang Mai ND ND ND ND ND ND ND ND
a Abbreviations: u, MLST type not present in the database; ND, not determined; n, novel sequence for this locus; UK, United Kingdom; PNG, Papua New Guinea;
CSF, cerebrospinal fluid.
b The 50% lethal doses (LD50) were determined by using a BALB/c mouse model (26). RAPD subtypes are denoted by letter designations in parentheses.
c Where known, the MLST group is indicated.
d Isolates in SSH.
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included B. pseudomallei isolates from Australia (26) and B. pseudomallei and B.
thailandensis isolates described previously (30). Further collections of 48 unchar-
acterized isolates from Thailand and 47 isolates mainly from Australia, each of
which represented a different MLST group, were used to test sequence distri-
butions by use of the VAT scheme (Table 1). Isolate 338 was included in this
analysis. All isolates used in the VAT analysis were isolated from different
patients.
Extraction of DNA. DNA was isolated from strains 338 and 520 for use in SSH
by the guanidium thiocyanate method, as described previously (25). Small-scale
isolation of DNA from the collection of Thai isolates was carried out with the
Wizard Genomic DNA Purification kit (Promega). DNA from the larger collec-
tion of mainly Australian isolates was extracted by using the QIAamp DNA mini
kit (QIAGEN).
MLST typing. MLST typing of 48 B. pseudomallei isolates from Thailand was
carried out by PCR amplification and DNA sequencing of the seven loci (ace,
gltB, gmhD, lepA, lipA, narK, and ndh) used in the published MLST typing
scheme (11). The loci were amplified by using the oligonucleotide primers and
conditions recommended at the website http://bpseudomallei.mlst.net/ and were
sequenced with the same primers. The search facility at http://bpseudomallei
.mlst.net/ was used to assign the sequences obtained to allele types and to screen
for previously reported MLST types. The MLST types for the 47 isolates mainly
from Australia were determined previously (6).
Construction and screening of subtraction libraries. SSH was carried out
with the CLONTECH PCR-Select bacterial genome subtraction kit (Clon-
tech) as recommended by the supplier, but with a hybridization temperature
of 73°C to take account of the high GC content of the organism. PCR
products obtained following SSH were cloned into pGEM-T (Invitrogen) to
produce a subtracted DNA library of RsaI fragments. Plasmid DNA from
individual clones was extracted and sequenced with vector primers by Lark
Technologies. Nucleotide sequences were analyzed for their presence in
genome sequence strains by using the BLASTN facilities at the websites
http://www.sanger.ac.uk/Projects/B_pseudomallei (B. pseudomallei K96243)
and http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi (B. mallei ATCC
23344 and B. thailandensis E264). BLASTX searches of the general database
were carried out by using the website http://www.ncbi.nlm.nih.gov.
PCR and M-PCR amplification. The oligonucleotide primers (Sigma-Genosys)
used in PCR assays and for the labeling of probes are listed in Table 2 and Table
S1 in the supplemental material, along with the annealing temperatures used.
Amplifications were carried out in an Eppendorf MasterCycler thermal cycler for
30 cycles consisting of 95°C (1 min), the annealing temperature (1 min), and 72°C
(2 min), with an additional extension time at 72°C (10 min) following completion
of the 30 cycles.
Dot blot hybridization. Dot blot hybridization of genomic DNA was carried
out as described previously (30) with a digoxigenin labeling and detection system
(Roche). Posthybridization washes were carried out by using stringent condi-
tions.
RESULTS
SSH between two Australian isolates. Two rounds of SSH
were carried out between strains 338 and 520, using each strain
in turn as the tester strain. In excess of 50 clones were se-
quenced for each of the subtractions. The presence or absence
of each of the nonduplicated subtracted sequences in the tester
and the driver strains was assessed by PCR assay. The results
of the SSH experiments are summarized in Table 3. We iden-
tified 20 sequences that were PCR positive for strain 338 but
PCR negative for strain 520 and 19 sequences that were PCR
positive for strain 520 but PCR negative for strain 338.
Distribution of subtracted sequences among a panel of
strains. Using PCR amplification assays, we studied the distri-
bution of 45 sequences from the subtractions between strain
338 and strain 520 among a panel of 19 B. pseudomallei isolates
and 14 B. thailandensis isolates (Table 1). The sequences
screened included 10 sequences that were PCR positive for
both strain 338 and strain 520 (Table 3), 5 of which were absent
from the genome sequence strain (K96243). Among B.
pseudomallei isolates, only strain 338 was PCR positive for
sequences 338-B1, 338-B3, 338-B8, 338-B20, 338-2A7, 338-
2B2, 338-2B4, 338-2B10, 338-2C3, and 338-2D9, whereas only
strain 520 was PCR positive for sequences 520-E12, 520-2E7,
520-2F2, and 520-E18. The distribution of the remaining se-
quences among the B. pseudomallei isolates, based on PCR
assays, is shown in Fig. 1. Interestingly, a single strain of B.
thailandensis was PCR positive for the sequences 338-B3 and
338-B8, both of which had been detected only in a single strain
of B. pseudomallei. B. thailandensis isolates were also PCR
positive for sequence 520-E35 (all 14 isolates), sequence 520-
2H3 (12 isolates), sequence 520-2E10 (11 isolates), sequence
338-2C5 (10 isolates), sequence 338-2D10 (8 isolates), se-
quence 520-2F6 (3 isolates), sequence 520-E16 (1 isolate), and
sequence 520-E19 (1 isolate). All other PCR amplification
tests conducted with the B. thailandensis isolates were negative.
Sequences 338-B4 and 338-B7 shared common distribution
profiles and matched putative genes located in close proximity
to each other, upstream from the previously reported genomic
island GI5 (12), and within RD6 (22) in strain K96243 (Table
3; Fig. 1). Sequence 338-B18, included in the distribution anal-
ysis, matched a sequence located in the previously reported
genomic island GI14 (12). All but three of the isolates tested
were PCR positive for this sequence (Fig. 1). All but one of the
isolates tested were PCR positive for sequence 520-E42, lo-
cated within GI7 (12).
Development of a VAT scheme. Using the information de-
rived from the distribution analysis we chose several sequences
that exhibited variation between strains of B. pseudomallei and
tested various primer set combinations with a view to devel-
oping M-PCR assays designed to give variable amplicon pro-
files. As a positive control we included a PCR assay for a
capsule gene (gmhA; Table 2). In addition, we included a PCR
assay for a putative transposase gene originally identified in
strain E503 (23) and known to have a variable prevalence
among B. pseudomallei strains (unpublished data) and PCR
assays for some of the genomic islands identified previously
(12). After testing numerous combinations of primers, we de-
veloped a strategy involving four separate M-PCRs (Fig. 2).
M-PCR1 is designed to assay for the gmhA-positive control
and the variable sequences 338-B7, 520-E42, and 520-E33.
M-PCR2 assays for the putative transposase from strain E503
and the variable sequences 338-2C5, 520-E35, and 520-2G9.
M-PCR3 assays for GI11 and the variable sequences 338-2D10
and 520-E36. Finally, M-PCR4 assays for GI12 and the vari-
able sequences 338-B3 and 520-2E10. Amplicon sizes are given
in Table 2. Overall, four sequences matched within or near
genomic islands, four sequences matched transposases, one
sequence was bacteriophage related, one sequence was DNA
helicase related, two sequences matched hypothetical proteins
of unknown function, and one sequence had no significant
match (Table 3).
Application of VAT to isolates from Australia and Thailand.
The 48 isolates of B. pseudomallei from Thailand were assigned
to an allele type for each of the loci ace, gltB, gmhD, lepA, lipA,
narK, and ndh (Table 1). With the exception of the lipA and
narK loci of one isolate (P14), all alleles matched a sequence
already deposited in the MLST database. The allele profiles
were used to assign 24 of the isolates to previously reported
MLST groups (Table 1). The 48 isolates could be subdivided
into 29 MLST groups, 11 of which contained more than one
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strain. Eighteen isolates had MLST profiles that were unique
among the collection of Thai isolates. The largest MLST
groups (sequence type 70 [ST70] and one MLST type previ-
ously unreported) comprised five isolates (isolates P20, P34,
P44, P42, and P49 and isolates P17, P21, P28, P31, and P41,
respectively). Four isolates (isolates P26, P39, P43, and P46)
shared MLST type ST10. None of the isolates from Thailand
shared an MLST type with any of the isolates from Australia.
The M-PCR assays for VAT were applied to DNA extracted
from strains of the two collections. Positive control DNA com-
prising individual or mixed DNA samples known to contain the
relevant sequences were included in each of the PCR amplifi-
cations, and each DNA sample was tested on a minimum of
two occasions. An amplicon was obtained from all DNA prep-
arations for the positive control capsule gene (M-PCR1) with
the exception of the preparation for B. thailandensis E52. The
full VAT profiles are available in Table S2 in the supplemental
material. The 95 B. pseudomallei isolates could be separated
into a total of 57 VAT types. The 48 isolates from Thailand,
comprising 29 different MLST groups, could be separated into
23 VAT types. The 44 isolates from Australia, comprising 44
different MLST groups, could be separated into 36 VAT types.
The five isolates from Thailand of ST70 could be subdivided by
their VAT profiles into three groups. Only one isolate (isolate
P42) was PCR positive for GI11, and only isolates P20 and P44
were PCR negative for sequence 338-2D10. Of isolates P17, P21,
P28, P31, and P41, which shared an MLST type, isolates P17, P28,
and P31 also shared common VAT profiles. However, isolate P21
differed by being PCR positive for GI11, and isolate P41 differed
by being PCR positive for sequence 338-B7, located upstream of
GI5. Of the four isolates sharing ST10, one isolate (isolate P39)
differed from the others in that it was PCR negative for GI11.
Another pair of isolates (isolates P33 and P35) that shared a
common MLST type also differed in their VAT profiles. How-
ever, four other pairs of isolates (isolates P12 and P48, P9 and
P47, P30 and P45, and P37 and P40) shared a common MLST
type and identical VAT profiles.
The prevalences of the VAT PCR amplicons are summa-
rized in Table 4. Some of the sequences included in the VAT
scheme were more commonly PCR positive among isolates
from one of the main geographical locations than among iso-
lates from the other. In particular, no isolate from Australia
was PCR positive for the putative transposase sequence
(TRANS) or GI11; a far higher proportion of Australian iso-
lates were PCR positive for sequences 520-E33, 520-2G9, and
520-E36 (all transposase related) and sequence 338-B3 (DNA
helicase related); a higher proportion of the isolates from
Thailand were PCR positive for sequences 338-B7 (near GI5)
TABLE 2. Oligonucleotide primers used for M-PCR amplification
M-PCR no.
and primer Sequence (5 to 3)
Amplicon
size (bp) Target A.T. (°C)
a Reference
or source
M-PCR1 58
146-5F ATCTGATCAGGACGCTTG 666 gmhA (BPSL2795b) (capsule) This study
146-5R CACTGCTTCCCGAAAATG
338-B7F ACTGGAATCGGGAAAAAC 482 338-B7 (near GI5) This study
338-B7R ACGATATTTTTCCGCTGC
520-E42F2 ATGCCGGCAGCGTCATAGA 257 520-E42 (GI7) This study
520-E42R2 ACAACGCATGCTTACAGTA
520-E33F GATCCATGACCACGGCCA 135 520-E33 This study
520-E33R AGGCCGAGAGTCTGATTG
M-PCR2 58
TRANSF TTTACCGAAGTCATGAGC 657 Transposase This study
TRANSR TTTGAAGTGCTGGTCGAC
338-2C5F AGCAATAAGCGGGCAAAA 403 338-2C5 This study
338-2C5R ATCACAAGCTATCCGCAG
520-E35F CTACTAGCCACTGATTCC 290 520-E35 This study
520-E35R ATAGATCATTCGTCCGAG
520-2G9F ACCTCGATTTTGCGTCTG 145 520-2G9 This study
520-2G9R AGAATGGCGTGGAGATTG
M-PCR3 58
338-2D10F2 ATGTCGTGCCTCCGTTCA 320 338-2D10 This study
338-2D10R2 ATGAGTCGGATCGGATCA
GI11BF TGTCGTGGCCCGGGGATTTGTA 238 BPSL3260b (GI11) 12
GI11BR TATTCGTTGCTTTCGCGTGTGGTC
520-E36F GTAATGACGCAAGACGCCG 132 520-E36 This study
520-E36R ACGGCCGAACACAAGAAC
M-PCR4 50
GI12F GCAATGGAATCGACGCAACATTG 788 BPSL3349b (GI12) 12
GI12R GACGCTGGCGGGTATGGGTAAG
338-B3F AATCAGACACTCGAGGAC 605 338-B3 This study
338-B3R ATAACCTGCTCGATTTTCC
520-2E10F CTCCACCGTGACGCTAAG 392 520-2E10 This study
520-2E10R GAGCACTTCACGCGTCTG
a A.T., annealing temperature.
b The GenBank accession number is given.
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TABLE 3. Summary of subtractive hybridization
SSHa sequence and
sequence type
Length
(bp)
GC
content
(%)b
Presence of
sequenced
genomec
Best BLASTX match; comments
(GenBank accession no.)
%
Identity
Length
(no. of
amino
acids)
E value
Bpm Bt Bm
Sequences present in strain
338 but not 520
Recombination related
338-B3 (DQ351720) 1,097 55.7    DNA helicase-related protein (Xanthomonas campestris)
(NP_637459)
32 364 2e45
338-2D1 760 57.8    DNA helicase-related (Xanthomonas campestris)
(NP637459); different region of same protein as 338-B3
72 248 7e83
338-B20 333 54.1    Uncharacterized protein (Rubrivivax gelatinosus)
(ZP_00241526); Membrane proteins, DNA
recombination protein RmuC (Salmonella and others)
(NP_457782)
80 110 4e43
54 110 5e26
Bacteriophage related
338-2C9 509 51.3  p  Putative transmembrane protein (Ralstonia solanacearum)
(NP_520413); DNA methylase of bacteriophage  E125
(B. thailandensis) (AAL47559)
74 50 1e15
96 28 3e8
Transcriptional
regulators
338-B7 482 54.8 1   DeoR family transcriptional regulator in RD6/GI5
(BPSL0939)
99 160 4.5e82
338-2C3 305 57.4    Transcriptional regulator (Ralstonia eutropha)
(ZP_00169018)
47 59 2e13
Enzymes
338-2A12 283 57.6    Maleylacetate reductase (Ralstonia sp.) (AAS87585) 55 68 4e16
338-2D9 480 59.2    Alcohol dehydrogenase (Polaromonas sp.) (ZP_00364129) 72 159 5e60
Hypothetical proteins
338-B8 425 50.6    Hypothetical protein (Escherichia coli O157:H7)
(NP_313283)
32 145 3e13
338-2C4 616 52.6    Hypothetical protein (Rhodopseudomonas palustris)
(NP_949350)
31 217 5e16
338-B4 282 53.9 1   Hypothetical protein in RD6/GI5 (BPSL0942) 100 88 2e42
338-2D7 624 48.9    Hypothetical protein (Chromobacterium violaceum)
(AAQ61798)
39 94 3e10
No significant BLASTX
matches
338-B1 190 50.0   
338-B16 374 48.1   
338-2A7 292 44.5   
338-2B2 429 50.4   
338-2B4 333 51.1 2  
338-2B7 426 57.5   
338-2B10 282 43.3   
338-2D3 331 52.3   
Sequences present in strain
520 but not 338
Mobile elements
520-E15 337 54.0    Putative transposase (Burkholderia fungoram)
(ZP_00283626)
75 29 1e7
520-E18 335 59.4 2p  p Putative transposase (BPSS2148) 97 49 8e21
520-E33 158 58.2 2   Putative transposase (BPSS2148); different region but
same protein as 520-E18
100 52 8.7e23
520-2F1 420 59.5 2   Putative transposase (BPSS2148); different region but
same protein as 520-E18 and 520-E33
99 128 2e66
Secretion related
520-E12 765 53.9    Hypothetical SecA-related protein (Photobacterium
profundum) (YP_133346)
48 218 2e53
Lipoprotein
520-E44 202 56.4 1   Putative lipoprotein (BPSL2045) 97 45 5e19
Enzymes
520-E19 759 53.9    Appr-1-p processing enzyme family (Nitrosomonas
europaea) (NP_841411); conserved hypothetical protein
(Synechocystis spp.) (NP_942395)
77 127 5e53
65 119 3e43
Continued on facing page
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and 520-2E10. Of the known genomic islands, GI11 was
present in only five isolates from Thailand and GI12 was
present in five isolates from Thailand and nine isolates from
Australia. In contrast, the distribution of GI7, as inferred from
the PCR assay results for sequence 520-E42, was more wide-
spread (Table 4).
The distribution of the sequences among the isolates from
Thailand indicated by PCR assays was confirmed by dot blot
hybridizations with digoxigenin-labeled probes for the sequences
gmhA, 520-E33, 338-B7, and 520-E42 (from M-PCR1); TRANS,
520-E35, and 520-2G9 (from M-PCR2); and 338-B3 and 520-
2E10 (from M-PCR4) (data not shown). The PCR assays for
GI11 and GI12 had been validated previously (12). From M-
PCR3, the sequence 520-E36 dot blots were less clear due to
background hybridization. We tested this sequence with a second
primer set and obtained the same distribution as before. Because
the PCR assay and dot blot data based on our initial primer set for
338-2D10 did not agree, new primers (primers 338-2D10F2 and
338-2D10R2) were designed and tested with the Thai isolates.
The distribution results corresponded to those obtained by using
dot blots; therefore, the new primer set was incorporated into
M-PCR3.
DISCUSSION
SSH between the two Australian isolates 338 and 520 iden-
tified 39 sequences that varied between the two isolates. The
subtracted sequences varied between 134 bp and 1,097 bp in
TABLE 3—Continued
SSHa sequence and
sequence type
Length
(bp)
GC
content
(%)b
Presence of
sequenced
genomec
Best BLASTX match, comments
(GenBank accession no.)
%
Identity
Length
(no. of
amino
acids)
E value
Bpm Bt Bm
520-E1 374 50.0 1p  p Conserved hypothetical protein (Synechocystis spp.)
(NP_942395); Appr-1-p processing enzyme family
(Nitrosomonas europia) (NP841411.1)
68 29 4e5
56 30 0.008
520-2F8 314 56.7 1 p  Molybdopterin oxidoreductase (BPSL2207) 100 54 3e25
Hypothetical or
uncharacterized
proteins
520-2E7 314 60.2    Uncharacterized protein (Microbulbifer degradans)
(ZP_00318360)
55 103 7e25
520-2F2 773 54.1 1   Hypothetical protein in RD7/GI6 (BPSL1146); variation
in the C terminus
80 111 7e40
520-2E10 (DQ351721) 519 54.0 1p   Hypothetical protein (BPSL2048) 49 123 6e26
520-E35 (DQ351716) 308 52.9    Hypothetical protein (BPSL2048A) 59 101 3e24
520-2G6 373 53.9    Hypothetical protein (B. mallei) (YP_105718) 47 113 1e23
No significant BLASTX
matches
520-E16 134 57.0   
520-E10 529 54.6   
520-2E1 233 52.8   
520-2F11 602 54.5   
520-2F6 814 50.7   
Sequences present
in strains 338
and 520
338-2D10 (DQ351718) 370 56.2    Bacteriophage protein from 1026b (B. pseudomallei
1026b) (NP_945078); bacteriophage protein from
E125 (B. thailandensis) (NP_536399)
87 100 3e47
84 100 6e45
338-2B9 663 47.1 2   Putative exported protein (BPSS0658) 100 162 4e78
520-E36 (DQ351719) 150 58.0    Putative transposase (Streptomyces avermitilis)
(NP_821845)
48 45 0.023
520-2G9 (DQ351717) 159 57.2    ISRSO16 transposase ORFB (R. solanacearum)
(NP_523187)
80 51 4e18
338-B14 181 54.1    Hypothetical protein (Methylococcus capsulatus)
(YP_115042)
90 31 6e9
338-B18 206 60.2 2   Hypothetical protein in GI14 (BPSS0655) 98 68 4e34
338-2A1 630 47.0 2 p  Hypothetical proteins (BPSS1753) 100 68 2e33
520-E42 303 54.1 1   Hypothetical protein in GI7 (BPSL1385) 100 71 7e34
No significant BLASTX
matches
338-B12 692 55.6   
338-2C5 429 51.3 1   Overlaps BPSL2558 by 10 bp but lies mainly in the gap
between BPSL2558 and BPSL2559
a GenBank accession numbers are indicated in parentheses for those novel sequences used in the VAT analysis.
b GC content for the subtracted sequence.
c The presence () or absence () of the subtracted sequence, based on 90% sequence identity by using BLASTN, is indicated for the genome-sequenced strains
of B. pseudomallei (Bpm), B. thailandensis (Bt), and B. mallei (Bm). For B. pseudomallei the number of the matching chromosomes is indicated. p, a partial match, where
the match does not extend over the entire length of the subtracted sequence.
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length, and all had a GC content (60.3%) below the aver-
age for the organism (68.1%). Among the 39 sequences were 7
matching sequences in chromosome 1 and 4 matching se-
quences in chromosome 2 of strain K96243. Analysis of the
genome sequence of B. pseudomallei K96243 suggests that
chromosome 1 contains a higher proportion of genes involved
in core functions, while chromosome 2 contains a higher pro-
portion of genes encoding accessory functions (12). However,
we found no bias toward chromosome 2 among those sub-
tracted sequences that matched the sequences of strain
K96243. In common with previous SSH analysis between non-
Australian isolates of B. pseudomallei, we identified several
variable sequences that matched transposases and bacterio-
phages (9). Prophages make a significant contribution to ge-
netic diversity in pathogenic bacteria (1–3). The temperate
bacteriophage E125 was originally identified in B. thailan-
densis as specific for B. mallei (31). More recently, bacterio-
phage 1026b was identified in B. pseudomallei and carries
genes for DNA packaging, tail morphogenesis, host lysis, inte-
gration, and DNA replication nearly identical to those of
E125, while those genes involved in head morphogenesis
differ from those of E125 (9). Two sequences exhibiting vari-
able prevalence among B. pseudomallei and B. thailandensis
shared similarity but not 100% identity with sequences from
these bacteriophages, suggesting that strain 338 and other iso-
lates of B. pseudomallei may carry related bacteriophages. Both
sequences matched a region shared by 1026b and E125 at
a nucleotide sequence identity of 94% (9). Interestingly, the
two subtracted sequences (338-2C9 and 338-2D10) did not
share the same distribution among the panel strains (Fig. 1),
and 338-2D10 was present in both strain 338 and strain 520
(Table 3).
We identified transposase-related sequences from the sub-
traction only using strain 520 as the tester (Table 3). Interest-
ingly, because of the approach to the initial screening of the
subtracted libraries that we chose, we identified a number of
FIG. 1. PCR-based distribution analysis of SSH sequences. Filled boxes indicate PCR-positive results.
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variable sequences, including two putative transposase-related
sequences, that were not genuinely subtracted. Often, libraries
generated following SSH are prescreened to identify tester-
specific sequences. Initially, for convenience, we took an ap-
proach whereby subtracted sequences were first sequenced and
then used to screen the genome sequence strain (B. pseudomal-
lei K96243) prior to the design of oligonucleotide primers for
PCR screening of tester and driver DNA. Our observations
suggest that the SSH procedure may enrich for regions with
low GC contents in a GC-rich genome among those se-
quences not genuinely subtracted. Hence, we were able to
identify some interesting sequences that were absent from the
genome sequence strain or that were variable among the panel
of isolates but that were not true subtracted sequences.
Our SSH analysis identified some sequences carried by the
genomic islands previously identified in strain K96243 (12).
Two additional islands were included in the VAT scheme. The
prophage-like islands GI7 (sequence 520-E42) and GI12 dif-
fered considerably in overall prevalence, with GI12 sharing a
similarly low prevalence with GI11, a putative integrated plas-
mid, or a conjugative element (12). However, our findings and
those of others (9) suggest that there may be other genomic
islands that are not present in strain K96243 but that exhibit a
variable prevalence between isolates. The contribution of such
islands and variable sequences to the variations in virulence or
clinical manifestations exhibited by different strains remains
unclear. However, our observations lend support to the notion
that horizontal gene transfer has played an important role in
the evolution of this pathogen.
Our VAT scheme is designed to give some indication of the
mobilomes of isolates while also providing a cheap, reproduc-
ible, and portable method for strain discrimination. We chose
to test the scheme with collections of isolates from Australia
and Thailand. The isolates from Australia, all of which were
different by MLST typing, have previously been used to dem-
onstrate a difference between B. pseudomallei isolates from
Australia and isolates from other regions of endemicity (6).
The isolates from Thailand were first characterized by MLST
typing in this study. Thus, some isolates that share the same
MLST types were included among the isolates from Thailand.
However, although some of these isolates also shared VAT
profiles, some had different VAT profiles, suggesting that iden-
tical molecular strain types may vary in their mobilomes. Sim-
ilarly, in some cases isolates of different strain types shared
VAT profiles.
Cluster analysis was used to gain an insight into the rela-
tionships between strains based on VAT profiles (Fig. 3). The
isolates cluster into groups, some of which are mainly or ex-
clusively from one of the main geographical origins and some
of which are mixed. Overall, there was a tendency for isolates
to cluster with those isolates from the same geographical lo-
FIG. 2. M-PCR analysis of B. pseudomallei isolates. The figure
shows agarose gels of example PCR amplicons derived from Thai
isolates (indicated above individual lanes) by M-PCR1 (a), M-PCR2
(b), M-PCR3 (c), and M-PCR4 (d). The first lane on each gel contains
a 1 kb-plus DNA ladder (Invitrogen). ve, positive control.
TABLE 4. Distribution of sequences among B. pseudomallei isolates
Isolate
% PCR positive
gmhA 338-B7 520-E42 520-E33 TRANS 338-2C5 520-E35 520-2G9 338-2D10 GI11 520-E36 GI12 338-B3 520-2E10
Original panel of B. pseudomallei 100 48 95 11 NDa 90 10 67 38 ND 48 ND 5 14
B. thailandensis (including E52) 0 0 0 0 ND 73 100 0 50 ND 0 ND 7 80
Australian isolates (n  44) 100 7 68 64 0 95 34 91 27 0 39 20 27 23
Thai isolates (n  48) 100 21 94 27 31 100 31 42 23 10 4 10 4 50
Other isolates (n  4) 100 25 75 50 0 100 25 100 0 0 75 0 0 25
Combined (n  96) 100 15 82 45 16 98 41 67 24 5 23 15 15 36
a ND, not determined.
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FIG. 3. Cluster analysis of VAT profiles. The VAT profiles were clustered by using a multivariate analysis for clustering of observations in the
MINITAB software package. A dendrogram was constructed by using average linkage and Pearson distance. One isolate of B. thailandensis (isolate
E52) was included in the analysis as an outlier. B. pseudomallei isolates P1 to P50 were from Thailand. All other isolates with the exception of
isolates 139 to 141 and 314 were from Australia. The cluster that includes the neurotropic isolates is bracketed.
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cation, suggesting a divergence in the mobilomes between iso-
lates from Australia and Thailand that is in agreement with the
apparently distinctive nature of isolates from Australia com-
pared to the nature of the isolates from southeast Asia (6).
However, the presence of minority isolates within clusters
dominated by one geographical origin and the existence of
some mixed clusters suggest that the picture is more complex.
In order to resolve this, it will be necessary to sequence more
B. pseudomallei genomes, especially those of Australian iso-
lates, and conduct comprehensive microarray surveys of col-
lections of isolates from different geographical locations.
Interestingly, one cluster included five isolates (isolates 668,
62, 983, 1153, and 332) from patients with the rare neurological
melioidosis presentation, which is a specific entity that can
occur in patients without risk factors (neurotropic isolates) (7).
Of these, three isolates (isolates 62, 983, 1153) had identical
VAT profiles, yet these three isolates and the other two neu-
rological melioidosis-related isolates all had different MLST
profiles (MLST groups ST129, ST148, ST142, ST117, and
ST106, respectively), with no two isolates sharing more than
three of the seven MLST alleles. To date, correlations between
isolates associated with melioidosis encephalomyelitis have not
been found by MLST or PFGE typing (4, 6). ST129, ST148,
ST142, ST117, and ST106 were widely distributed in a dendro-
gram showing the results of cluster analysis based on MLST
allele profiles and, apart from ST117 and ST129, were also
widely distributed on a tree constructed from concatenated
sequences (6). Furthermore, other isolates within the VAT
cluster containing the five neurotropic isolates were mostly
associated with more severe disease, including three isolates
(isolates 1161, 64, and 944) that were associated with bacter-
emic pneumonia with septic shock. This suggests that the con-
tent of the accessory genome may play an important role in
determining the clinical manifestations of some forms of mel-
ioidosis and that this can be independent of the conserved
genome. Although the data obtained in this study are insuffi-
cient to identify specific genes or activities that might contrib-
ute to the success of the isolates causing disease of the central
nervous system, we can discount the need for genomic islands
GI11 and GI12, which were absent from these isolates.
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